Cardiovascular Drugs: Products, Applications and New Developments

Report Highlights

• Worldwide sales of cardiovascular drugs approached $47 billion in 1999, and the leading 15 products in the class generated sales of approximately $18 billion. Cardiovascular drugs discussed in this report comprise adrenergic inhibitors, adrenergic stimulators, angiotensin converting enzyme (ACE) inhibitors, angiotensin II inhibitors, antithrombics, beta blockers, calcium channel blockers, diuretics, steroids and steroidal glycosides, vasodilators, vasopressors, and others.
• Market applications reviewed in this report include acute coronary syndrome, angina, arrhythmia, atherosclerosis, congestive heart failure, coronary artery disease, deep vein thrombosis, edema, hypercholesterolemia, hypertension, hypotension, myocardial infarction and stroke.
• Angiotension II inhibitors, which are indicated for the treatment of heart failure and hypertension, are projected to see an average annual growth of nearly 20% and the antithrombic category will see growth approaching 16% throughout the forecast period (2000-2005).

INTRODUCTION

STUDY GOAL AND OBJECTIVES

This study provides a comprehensive analysis of available and emerging pharmaceutical treatments for cardiovascular diseases. Its aim is to provide a range of information - from detailed product analyses through industry trends - to quantify and qualify the market for cardiovascular drugs. Forecasts of product categories are provided for the worldwide prescription market. Forecasts and trends are gleaned from interviews with industry sources as well as from considered assessment of available and emerging technologies.

REASONS FOR DOING THE STUDY

The cardiovascular drug market has been the leading drug category in sales for the past two decades. A continuous flow of new and effective drugs has kept this sector in its number one position and will continue to do so throughout the forecast period. The cardiovascular drug category was bolstered in the 1990s by the introduction of highly effective anticholesterol statin drugs and angiotensin II inhibitors, which displaced older drugs and spurred market growth.

Expanding indications for existing products is a trend of the new millennium in many drug categories, including this one. Further, earlier treatment of persons with high cholesterol and hypertension - before the development of serious disease - is broadening usage and revenues in certain classes of agents. An aging population continues to expand the market for drugs to treat cardiovascular disorders, which occur predominantly in older people. New technologies, including new types of surgeries and, eventually, gene therapy to treat cardiovascular disorders, will displace some pharmaceuticals and perhaps entire categories of drugs. Finally, ongoing discoveries about the nature of cardiovascular diseases - such as the implicated role of microorganisms, the expanded understanding of the function of hemoglobin and the importance of the amino acid homocysteine - indicate a dynamic change in the treatment of some cardiovascular diseases.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This report provides a thorough background in the cardiovascular drug market, offering information needed to understand the current market and to approach the emerging one. It is an invaluable tool for planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants and anyone interested in the cardiovascular pharmaceuticals market, its products, its industry participants and its future.

SCOPE AND FORMAT

This report on the cardiovascular drug market covers the following categories of cardiovascular agents:

• Adrenergic inhibitors
• Adrenergic stimulators
• Angiotensin converting enzyme (ACE) inhibitors
• Angiotensin II inhibitors
• Antithrombotics
• Beta blockers
• Calcium channel blockers
• Diuretics
• Steroids and steroidal glycosides
• Vasodilators
• Vasopressors
• Others

Market applications reviewed in this report include:

• Acute Coronary Syndrome
• Angina
• Arrhythmia
• Atherosclerosis
• Congestive Heart failure
• Coronary Artery Disease
• Deep Vein Thrombosis
• Edema
• Hypercholesterolemia
• Hypertension
• Hypotension
• Myocardial Infarction
• Peripheral Artery Disease
• Stroke

Not included in this report is information on products for blood disorders other than hypercholesterolemia, such as treatments for anemia, hemophilia, etc.

Market figures are based on revenues at the manufacturers' level and are projected at year 2000 dollar value - that is, inflation is not computed into the projection figures.

Trends are assessed based on projected sales for new product introductions, increased ratios of generic products and subsequent declining prices in some categories, expanded or altered usage of certain drugs and categories of agents, projected increases in the prevalence of certain diseases and the effect of new technologies and products on those currently available, among other factors.

Included in this report are forecasts by product segment from 1999 through 2005, including supporting analyses for all projections.

The study is arranged to offer an overview of the cardiovascular drug market accompanied by analyses and forecasts by product type and application. Selected international markets are discussed, as well as information on industry structure and the regulatory environment. Profiles of manufacturers of leading cardiovascular agents as well as of biotechnology companies with novel products in development provide information on placement of current leading participants within the market and strategic analyses of emerging companies.

METHODOLOGY

Information to prepare this study was derived from data supplied by product managers, marketing strategists, research executives and others at leading companies in the cardiovascular drug industry. Information was also obtained from researchers and product planners at companies that do not yet participate in this market but which have products in development that are poised to be introduced during the forecast period. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate cardiovascular diseases and their treatment. Surveys of prescribing practices of physicians and pharmacists were reviewed to assess prescribing practices and opinions on products. Searches of secondary material such as company annual reports and 10Ks, journal articles, prospectus assessments, government resources and data from health care institutions were also conducted.

INFORMATION SOURCES

Information to prepare this report was obtained from participating and emerging companies in the area of cardiovascular drugs; industry analysts; health care personnel; the National Heart, Lung, and Blood Institute; the American Heart Association; the Centers for Disease Control and Prevention, and other government agencies; literature searches; annual reports; 10Ks; and product literature.